Oncology
Survivin may be suited for tumor-specific gene promotion in melanoma
Published in Cancer Weekly, April 19th, 2005
"Gene therapy is a novel therapy for melanoma. To date, however, there is still no powerful tumor specific promoter (TSP) to restrict the transgene expression in melanoma cells. In order to define a useful TSP for targeting in the context of melanoma gene therapy, four promoters, the cyclooxygenase-2 (Cox-2), alpha-chemokine SDF-1 receptor (CXCR4), epithelial glycoprotein 2 (EGP-2), and survivin, were tested in both established melanoma cell lines and primary melanoma cells," investigators in the United States report.
"We employed recombinant adenoviral vectors (reAds) each with a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-04-19)
More Articles from Cancer Weekly
- Cancer Genetics
Scientists uncover how BRCA2 regulates DNA repair - Liver Tumorigenesis
Liver tumorigenesis modulated in connexin32-deficient mice - Lung Cancer
Smoking implicated with ERCC1 polymorphisms and an increased risk of lung cancer - Melanoma
Chromosome locus identified as possible bearer of genes key to tumorigenesis - Mouse Skin Carcinogenesis
Antitumorigenic role for murine 8S-lipoxygenase in skin carcinogenesis - Acute Lymphocytic Leukemia
Clofarabine's interim results in leukemia reported at symposium - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
